Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782945 · ClinicalTrials.gov registry record
Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms
A clinical trial of Moderate Gastrointestinal Discomfort, sponsored by Biohm Technologies.
- Active
- Registry status
- 141
- Enrollment target
- 1
- Study location
NCT06782945: Active study of Moderate Gastrointestinal Discomfort, sponsored by Biohm Technologies.
NCT06782945 is a study of Moderate Gastrointestinal Discomfort that is active but no longer recruiting, run by Biohm Technologies. The registered enrollment target is 141 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782945, a study of Moderate Gastrointestinal Discomfort, is active but no longer recruiting, sponsored by Biohm Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale for this study is to observe the effect of two different doses of a consumer-grade probiotic product called FX Probiotic Blend on digestive symptoms in individuals with moderate gastrointestinal discomfort. Additionally, the study aims to observe the effects of the probiotic product on anxiety and quality of life, as well as effects on gut microbiota via activities and technologies that can successfully and effectively be completed and utilized in a home setting. Because this product is currently available in the overt the counter (OTC) market across the United States, a consumer-driven, decentralized observational clinical research study is therefore well-suited for examining the effects of this probiotic product in this population.
Primary Outcome
Change in the Gastrointestinal Symptom Rating Scale (GSRS) score between placebo and study product groups. Baseline period will be compared as well as GSRS scores between the two doses. The score is calculated by using a 7-point Likert scale to rate the frequency and intensity of symptoms experienced over the previous week. A higher score indicates more severe symptoms and worse outcomes.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT BIOHM FX Probiotic Blend
Study Locations (1)
California
- People Science, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2025-03-04 |
What the registry record for NCT06782945 still lists
NCT06782945 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Moderate Gastrointestinal Discomfort appearing as the primary indexed condition, and to 1 intervention - of which BIOHM FX Probiotic Blend is the first listed.
NCT06782945 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06782945 about?
NCT06782945 is a clinical study titled "Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms". The rationale for this study is to observe the effect of two different doses of a consumer-grade probiotic product called FX Probiotic Blend on digestive symptoms in individuals with moderate gastrointestinal discomfort. Additionally, the study aims to observe the effects of the probiotic product on...
What is the current status of trial NCT06782945?
This trial is currently active not recruiting. The enrollment target is 141 participants. The study started on 2024-07-24. Estimated completion is 2025-03-04.
What conditions does trial NCT06782945 study?
This clinical trial studies the following conditions: Moderate Gastrointestinal Discomfort.
What interventions are being tested in trial NCT06782945?
The interventions under investigation include: BIOHM FX Probiotic Blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06782945?
This trial is sponsored by Biohm Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782945 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI